Abstract B039: APEX2 is a synthetic lethal target for RNASEH2B-deleted or BRCA-mutant tumorsAntoine Simoneau, Teng Teng, Hsin‐Jung Wu et al.|Molecular Cancer Therapeutics|2025Cited by 2
Abstract B098: Unbiased in vitro and in vivo drug anchor screens identify mechanisms of resistance and sensitization for MTA-cooperative PRMT5 inhibitors in MTAP-deleted cancer modelsSteven Lombardo, Teng Teng, Matthew R. Tonini et al.|Molecular Cancer Therapeutics|2023Cited by 0
Abstract C048: Inducible activation of sgRNA libraries in tumor xenografts empowers large-scale in vivo target discovery screensSilvia Fenoglio, Teng Teng, James M. Tepper et al.|Molecular Cancer Therapeutics|2023Cited by 0
Tumor suppressor collateral damage screens reveal mRNA homeostasis protein HBS1L as a novel vulnerability in ch9p21 driven FOCAD deleted cancerHongxiang Zhang, Teng Teng, Matthew R. Tonini et al.|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 0
Temporal control of sgRNA library activation unlocks large-scale <i>in vivo</i> CRISPR screensSilvia Fenoglio, Teng Teng, Yi Yu et al.|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 0